Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010.

    ... advanced age, male gender, and antecedent exposure to chemotherapy or radiation as treatment for other cancers, which alone ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.

    ... ( azacitidine and decitabine ), intensive chemotherapy (ICT), and allogeneic stem-cell transplantation (alloSCT). ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes.

    ... prognosis. The mainstay of treatment includes cytoxic chemotherapy and supportive care . Over the last decade, promising ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Prognosis of myelodysplastic syndromes.

    ... or those who have been exposed to prior forms of chemotherapy . It is therefore crucial to develop clinical tools to predict ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Infections in patients with aplastic anemia.

    ... with AA and the patient who is neutropenic due to chemotherapy and this leads to a difference in the infections that they ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes.

    ... therapies include cytarabine-based remission induction chemotherapy and hematopoietic stem cell transplantation. Transplantation ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. How we treat higher-risk myelodysplastic syndromes

    ... hypomethylating agent therapy, induction chemotherapy or a clinical trial should be considered to prevent ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.

    ... (CCR), which included low-dose ara-C, BSC, or intensive chemotherapy . In both studies, azacitidine dose was 75 mg/m(2)/d SC for 7 ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany.

    ... yrs were more likely to receive active therapies (i.e., chemotherapy , immunomodulatory therapy, or epigenetic therapy) than ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of ...

    Research Article last updated 07/20/2018 - 5:14pm.